Rhodiola rosea for Health & Longevity

Evidence Review created on 10/09/2026 using AI4L + evidence-mcp / Sonnet 5.5

Also known as: Rhodiola, Golden Root, Roseroot, Rosenroot, Arctic Root, Rose Root, Sedum roseum

Motivation

Rhodiola rosea (golden root, roseroot) is a flowering plant of cold, high-altitude regions of Europe, Asia and North America. Its root has long been a herbal remedy and is now sold as a dietary supplement, usually as an extract with fixed amounts of its two main compound groups, rosavins and salidroside. It interests health- and longevity-oriented adults because it is promoted as a way to build resilience to physical and mental stress.

Traditional medicine in Scandinavia, Russia and Central Asia used the root for fatigue and endurance, and Soviet-era researchers later grouped it with plants thought to raise general resistance to stress. More recently, researchers have tested it in people for fatigue and exercise performance, and in fruit flies and worms for effects on lifespan, which is why it appears in longevity discussions.

This review examines what human and laboratory studies show about Rhodiola rosea as an intervention for health and longevity: how it is thought to work, which benefits and risks have been reported and how strong the evidence is, how products and doses are used, and which studies are under way.

Benefits - Risks - Protocol - Conclusion

Expert commentary and overview articles that discuss Rhodiola rosea in depth.

Five qualifying sources are listed. No substantial content was found from Peter Attia (his site search returned no results for Rhodiola), Chris Kresser (only a short mention inside a broad article on nootropics) or Lifespan.io (Rhodiola appears only in coverage of a multi-ingredient product).

Grokipedia

Rhodiola rosea

Plant, traditional-use and pharmacology overview, including the usual extract standard of 3% rosavins and 1% salidroside, and a summary that human evidence is limited to moderate while longevity claims rest on animal work.

Examine

Rhodiola rosea benefits, dosage, and side effects

Evidence-graded summary of 21 trials and two meta-analyses (pooled analyses of earlier trials), updated December 2025, with dosing ranges and a note that doses above 680 mg may be less effective.

ConsumerLab

Rhodiola Supplements Review & Top Picks

Independent testing of 13 Rhodiola supplements for rosavin and salidroside content, with a January 2026 update on quality concerns; full results require a paid membership.

Systematic Reviews

Systematic reviews (structured appraisals of all eligible studies) of Rhodiola rosea in humans, identified through PubMed.

No systematic review or meta-analysis focused on the safety of Rhodiola rosea was found, so the principal risk is unrepresented; safety is reported only within the efficacy reviews above.

Mechanism of Action

Rhodiola rosea root contains about 140 compounds; the best studied are the rosavins and salidroside. Extracts are classed as adaptogens (substances claimed to raise general resistance to stress) (Panossian et al.). Proposed mechanisms:

  • Stress-hormone control: The extract may blunt the cortisol (main stress hormone) response through the hypothalamic-pituitary-adrenal (HPA) axis (the brain-to-adrenal stress-hormone system); Olsson et al. (co-authored by an extract-maker researcher) reported a smaller waking cortisol response than placebo in 60 burnout patients.
  • Cell stress pathways: In worms, extract moved DAF-16 (a stress-response regulator, called FOXO in mammals) into the cell nucleus, which may raise heat shock proteins (protective repair proteins), consistent with hormesis (a mild stress that triggers protection) (Wiegant et al.).
  • Brain chemistry: Extracts inhibited monoamine oxidase (MAO; enzymes that break down serotonin and dopamine) in vitro (in laboratory dishes) (van Diermen et al.), but salidroside at expected blood levels did not, in a study by a salidroside producer’s scientists (Kasprzyk et al.).
  • Competing view: Placebo groups improved in Olsson et al. and Mao et al., so expectation may explain some improvement.

Pharmacology: no human half-life exists; salidroside’s was about 1 hour in rats after intravenous dosing, with kidney clearance, reaching muscle, fat and gonads; about half was unrecovered (metabolism likely), and no human metabolic pathway or enzyme is published (Zhang et al.). Effects are broad rather than selective (Panossian et al., 2021). In 13 volunteers, a commercial product lowered CYP2C9 (a liver enzyme that clears many drugs) activity (Thu et al.).

Historical Context & Evolution

  • Original use: Used for centuries in Russia and Scandinavia, traditionally for fatigue (Panossian et al.); a drug monograph dates its first written record to the Greek physician Dioscorides and notes Linnaeus described it as an astringent (a tissue-tightening agent).
  • Route to health optimization: Soviet-era researchers developed the adaptogen concept in the mid-20th century (Panossian et al., 2021), and groups in Russia, Armenia and Sweden, several with authors linked to the extract’s maker, later tested standardized extracts in stressed students (Spasov et al.), physicians (Darbinyan et al.) and cadets (Shevtsov et al.), reporting less fatigue and better mental performance than with placebo. A fruit-fly study reporting longer lifespan on Rhodiola added a longevity framing (Jafari et al.).
  • Evolution of opinion: Early trials reported benefits. A 2011 systematic review found possible benefit but no independent replications; later independent trials were mixed, with null or negative results (Shanely et al., Punja et al., Mao et al.) alongside favorable ones (Noreen et al., Cropley et al.).
  • Regulators and guidelines: The European Medicines Agency (EMA) accepts it as a traditional herbal medicine on long-standing use, citing shortcomings in small clinical studies (EMA); a 2022 guideline taskforce of psychiatric societies, with no identified revenue from Rhodiola sales, did not support it for mood disorders. Newer exercise trials keep the question open (Tinsley et al.).

Expected Benefits

High 🟩 🟩 🟩

Endurance Exercise Performance ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

A single dose an hour before exercise modestly improved time to exhaustion and timed efforts in healthy young adults; this bears on athletic performance, not longevity. Independent groups found this (De Bock, Leuven; Noreen, Gettysburg). A meta-analysis of 26 trials averaging 33 days favored Rhodiola, but four weeks of daily dosing added nothing in De Bock’s trial, 30 days of 600 mg/day left marathon time unchanged, and SHR-5 during heat acclimation (adapting to heat) did not change time to exhaustion. Net: acute dosing gives small gains; daily use is inconsistent.

Magnitude: Meta-analysis of 26 trials (668 healthy participants): effect size (a unit-free measure of group difference) 0.38 (95% CI, the range likely to contain the true value: 0.07 to 0.69) for time to exhaustion and −0.40 (95% CI −0.78 to −0.01) for fixed-distance timed efforts, where negative means faster, versus control. Single-dose crossover trial (each person received both treatments): timed 6-mile cycling effort 0.4 minutes faster than placebo (25.4 versus 25.8 minutes, p = 0.037; the p-value is the probability of a difference this large arising by chance alone, and below 0.05 is conventionally called statistically significant) (Noreen). Parallel trial (separate groups received each treatment) of 30 days at 600 mg/day: marathon time 3.87 versus 3.93 hours with placebo, not significantly different (p = 0.722) (Shanely).

Medium 🟩 🟩

SHR-5 extract improved burnout scores and attention versus placebo in Olsson (60 adults) and mental performance in Darbinyan (56 physicians), with similar findings from Spasov and Shevtsov, all co-authored by researchers linked to the extract’s maker. An independent trial in 48 nursing students found fatigue worse than with placebo, Cropley found no cognitive-test difference from no treatment in 80 anxious adults, and a systematic review found design or reporting flaws in every trial. Net: favorable results cluster in one network’s trials, and the one independent placebo-controlled trial was negative.

Magnitude: Independent trial of 48 nursing students: vitality score change 17.3 points lower than with placebo at day 42 (95% CI −30.6 to −3.9). Single-dose trial of 161 cadets: antifatigue index (a mental-performance ratio; higher means less fatigue) 1.04 with the standard dose versus 0.90 with placebo (Shevtsov).

Strength & Power in Resistance-Trained Adults ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

In a crossover trial of 27 resistance-trained adults, Rhodiola raised one-repetition maximum (the heaviest single lift), repetitions to failure (repetitions until the muscles give out) and Stroop scores (a color-word attention test), regardless of dose or gender; Wingate cycling power (a 30-second all-out test) showed no consistent effect. A crossover trial in 10 resistance-trained men found faster bar speed but fewer repetitions to failure on Rhodiola. This bears on athletic performance and attention, not longevity. Net: maximal-strength gains rest on one trial, and repetition endurance results conflict.

Magnitude: Versus a no-capsule control, low-dose Rhodiola added 5.59 kg to bench-press one-repetition maximum (p = 0.003) and 35.7 kg to leg-press maximum (p < 0.001); high-dose added 47.7 kg to leg-press maximum (p < 0.001); leg-press contrasts against placebo were also significant (Koozehchian). In the 10-man trial, 1,500 mg/day for 3 days plus 500 mg before testing raised mean bench-press velocity versus placebo (p = 0.046) but lowered total repetitions to failure (p < 0.001); the abstract gives no group figures (Williams).

Anxiety Symptoms

Cropley randomized 80 mildly anxious adults to 400 mg/day or no treatment and found lower self-reported anxiety, stress and anger at 14 days, without a placebo. Bystritsky saw lower anxiety ratings in 10 patients, with no control group.

Magnitude: Direction only: lower self-reported anxiety than no treatment at 14 days (Cropley, no placebo) and a significant fall in mean Hamilton Anxiety Rating Scale score (a clinician-rated scale) over 10 weeks (Bystritsky, p = 0.01, no control group); the published reports available give no score differences, so no outcome figure is stated.

Low 🟩

Depressive Symptoms (Mild to Moderate) ⚠️ Conflicted

Darbinyan found lower scores than placebo (89 patients) and Gao greater improvement when a Rhodiola capsule (species unstated) added to sertraline, but Mao found no difference (57 patients); a psychiatric-society guideline taskforce (no revenue link found) did not support it. Net: benefit as sole treatment was not reproduced.

Magnitude: Hamilton depression score (a clinician-rated scale) fell 5.1 points (95% CI −8.8 to −1.3) with Rhodiola and 4.6 points (95% CI −8.6 to −0.6) with placebo; the difference between groups was not significant.

Speculative 🟨

Lifespan Extension in Invertebrates

Fruit-fly lifespan rose 14–17% and worm lifespan 10–20% at moderate doses, with shortening at high doses. No human lifespan or aging-outcome data exist.

Senescent-Cell Clearance in Mice

An extract cleared senescent cells (aged cells that stop dividing) in mice; cell-culture assays traced the activity to tea-catechin oligomers (short chains of tea polyphenols), untested alone in mice. Basis is animal work only.

Antioxidant & Muscle-Damage Markers ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Bears on exercise recovery, not longevity. A meta-analysis found more antioxidant capacity, less malondialdehyde (oxidative-damage marker) and creatine kinase (muscle-damage marker); a marathon trial found no creatine kinase or soreness change. Net: unvalidated, inconsistent markers.

Cortisol Response to Stress ⚠️ Conflicted

Olsson reported a smaller cortisol response on waking than placebo in 60 patients, while Noreen found no difference around exercise. Cortisol shifts are unvalidated against clinical outcomes. Net: results are inconsistent across settings.

Benefit-Modifying Factors

  • Genetics: No genetic variant has been shown to modify benefit. CYP2C9 variants change how strongly the extract inhibits that enzyme (Thu et al.), which affects medication exposure rather than efficacy.
  • Baseline biomarkers: No blood marker predicts response; trials selected participants by fatigue, burnout or depression scores (Olsson et al.).
  • Sex: About three quarters of participants in sports trials were men (Sanz-Barrio et al.); one dose-response trial (testing several doses) in resistance-trained adults reported gains regardless of gender (Koozehchian et al.).
  • Pre-existing conditions: Stress, fatigue and burnout trials enrolled affected people, whereas endurance gains were seen in healthy adults; depression results were mixed (Mao et al.).
  • Age: Trials mostly enrolled adults near age 22 (Wang et al.); benefit at the older end of the target range is unstudied.
  • Dose, timing and training status: Larger gains in peak oxygen use occurred above 600 mg/day, and trained participants had lower muscle-damage markers (Wang et al.); four weeks of daily use added nothing to acute dosing (De Bock et al.).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the human data are mild, nonspecific adverse events in small trials, without replicated excess over placebo from independent groups.

Medium 🟥 🟥

Reduced CYP2C9 Activity (Altered Drug Exposure)

In a crossover study of 13 healthy volunteers, 14 days of a commercial extract lowered CYP2C9 activity, measured as conversion of losartan (a blood-pressure drug) to its active form, while four other drug-clearing enzymes were unaffected. The authors judged the effect modest but possibly relevant for drugs with a narrow safety margin, such as warfarin (a blood thinner) and phenytoin (an anti-seizure drug). Evidence comes from one research group and one product.

Magnitude: 21% decrease in the active-metabolite-to-losartan ratio after 14 days compared with no pretreatment (statistically significant), larger in extensive metabolizers (people with typical-to-high CYP2C9 activity) than in intermediate and poor metabolizers; no significant change for the other four enzymes.

Low 🟥

Mild Adverse Events ⚠️ Conflicted

Dizziness and dry mouth are reported most often, as in Bystritsky (uncontrolled). Punja found adverse events no different from placebo, Olsson no serious ones attributable to the extract and Darbinyan none, while Mao found numerically more with Rhodiola than placebo (untested). Net: effects are mild and not consistently above placebo.

Magnitude: Adverse events occurred in 30.0% with Rhodiola versus 16.7% with placebo (63.2% with sertraline) in a 12-week trial of 57 people with depression; Punja reported no difference in total events (no figures in the abstract); Bystritsky’s 10 patients had no control group.

Product Adulteration & Contaminants

Analyses of commercial products found missing or low rosavin, species substitution (Booker et al.), and trace arsenic, cobalt and lead (Porwollik & Jafari). No clinical harm has been documented; evidence is indirect because it measures products, not patients.

Magnitude: About one fifth of roughly 40 products labelled as Rhodiola rosea in Europe lacked rosavin, and about 80% of the rest had lower rosavin than registered products; in a U.S. sample, rosavins ranged from 0.01% to 3.08% and all seven capsule products had trace arsenic, cobalt and lead.

A case report describes a 68-year-old woman who developed restlessness and trembling, read by the authors as possible serotonin syndrome (a state of excess serotonin activity), after adding Rhodiola to paroxetine. Extracts inhibit monoamine oxidase in vitro. Evidence is one uncontrolled report.

Magnitude: Not quantified in available studies. Only a single case report exists, and no controlled study has measured this outcome.

Mania or Hypomania

A case report describes a 58-year-old man with no reported psychiatric treatment, hospitalized with mania (abnormally elevated mood and energy; hypomania is the milder form) after taking about three times the recommended dose. Extracts inhibit monoamine oxidase in vitro; risk in bipolar disorder is inferred. Evidence: one uncontrolled report.

Magnitude: Not quantified in available studies. Only a single case report exists, and no controlled study has measured this outcome.

Speculative 🟨

Blood Pressure or Glucose Lowering ⚠️ Conflicted

ConsumerLab notes caution with blood-pressure and diabetes medicines, yet a crossover trial found no consistent acute blood-pressure effects. Net: the caution rests on labeling, not documented events.

Risk-Modifying Factors

  • Genetics: CYP2C9 status modifies the enzyme effect, which was larger in extensive metabolizers than in intermediate or poor metabolizers (Thu et al.); no genetic effect on adverse events is known.
  • Baseline biomarkers: Baseline blood pressure and glucose matter mainly for people on lowering medication; no biomarker has been shown to predict adverse events.
  • Sex: No sex-specific safety analyses were found; pregnancy and lactation safety information is lacking (Drugs.com).
  • Pre-existing conditions: A case report describes mania at about three times the usual dose; bipolar disorder is a theoretical concern; ConsumerLab flags low blood pressure, diabetes and antidepressant use, and the CYP2C9 data flag warfarin use.
  • Age: Safety data come mostly from adults in their 20s and 30s; older adults often take several medicines, which raises interaction exposure.
  • Dose: Lifespan studies found shortening at high doses in flies (Gospodaryov et al.) and worms (Wiegant et al.); human dose-related harm is undocumented.

Key Interactions & Contraindications

  • Warfarin and phenytoin, caution (theoretical): CYP2C9 clears both, and Rhodiola inhibited it in volunteers (Thu et al.), but neither drug was tested. Possible consequence: higher drug levels, bleeding or toxicity. Mitigation: closer INR (international normalized ratio, a clotting test) checks.
  • Losartan (blood-pressure drug), monitor: Conversion to the active form fell 21% in volunteers (Thu et al.); Drugs.com lists possibly raised losartan levels, no action needed. Consequence: altered blood-pressure control. Mitigation: home blood-pressure checks.
  • Other CYP2C9-cleared prescription drugs (celecoxib, glipizide), caution (theoretical): Same enzyme pathway, no studies. Consequence: modestly higher drug exposure. Mitigation: pharmacist or prescriber review.
  • Antidepressants (paroxetine), caution: One case report describes restlessness and trembling after adding Rhodiola to paroxetine (Maniscalco et al.). Consequence: possible serotonin excess. Mitigation: prescriber review before combining.
  • MAO inhibitors (phenelzine, drugs that block MAO), avoid (theoretical): Extracts inhibit MAO in vitro (van Diermen et al.); no human study exists. Consequence: possible serotonin excess. Mitigation: avoiding the combination.
  • Blood-pressure drugs (amlodipine, lisinopril) and glucose-lowering drugs (insulin, glipizide), monitor (theoretical): ConsumerLab notes caution; trials show no consistent blood-pressure effect. Consequence: additive low blood pressure or low blood sugar. Mitigation: home readings.
  • Over-the-counter ibuprofen, caution (theoretical): CYP2C9 clears it; no studies. Consequence: modestly higher drug exposure. Mitigation: the lowest effective analgesic dose.
  • Over-the-counter caffeine, omeprazole (acid reducer) and dextromethorphan (cough suppressant), no interaction found: A volunteer study found no significant change in CYP1A2 (clears caffeine), CYP2C19 (omeprazole), CYP2D6 (dextromethorphan) or CYP3A4 (midazolam and many drugs) activity (Thu et al.).
  • Supplements with additive effects, monitor (theoretical): Ashwagandha may also lower blood pressure (ConsumerLab); St John’s wort, 5-hydroxytryptophan (a serotonin precursor) and S-adenosylmethionine (a mood supplement) add serotonin-raising effects; guarana and yohimbine add stimulation. Mitigation: adding one product at a time.
  • Other interventions, no interaction found: Interactions with fasting, sauna or training programs have not been studied, so no consequence is documented; exercise is the main studied context (Tinsley et al.).

Populations who should avoid Rhodiola rosea:

  • People under 18 years of age: the EMA limits use to adults over 18 (EMA).
  • Pregnancy and lactation: safety and effectiveness information is lacking (Drugs.com).
  • Bipolar disorder (theoretical): based on stimulation and in vitro MAO inhibition; one case report describes mania at about three times the usual dose (Whig & Leo); no number applies.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Verified products: Choosing extracts backed by a certificate of analysis or independent testing addresses the adulteration and metal contamination found in U.S. products (Porwollik & Jafari).
  • Dose ceiling: Examine suggests keeping doses at or below 680 mg/day because higher doses may lose effect, which limits exposure at doses with unclear safety.
  • Low starting dose: Starting at 100–200 mg daily for several days reveals dizziness or dry mouth at low exposure.
  • Medication review: A pharmacist or prescriber review of CYP2C9-cleared drugs (warfarin, phenytoin, losartan) addresses raised drug exposure.
  • INR and blood-pressure checks: An INR recheck 1–2 weeks after starting for people on warfarin, and weekly home readings for those on blood-pressure drugs, catch altered drug effect.
  • Bipolar disorder exclusion: Exclusion in bipolar disorder, and discontinuation if sleep need falls or restlessness rises, addresses mood elevation.
  • Short course: The EMA advises seeking medical advice beyond two weeks of use (EMA), which limits unstudied long-term exposure.

Therapeutic Protocol

Each dose below is cited to its source; other parameters without a citation (timing, cycling, titration steps) reflect common practice.

  • Stress-related fatigue (SHR-5): 576 mg/day (four tablets) for 28 days (Olsson et al.); one tablet (about 144 mg, Examine) daily for two weeks in Darbinyan et al.; developed by the Swedish Herbal Institute.
  • Life-stress and burnout (WS 1375): 200 mg twice daily for 4 weeks (Edwards et al.); 400 mg/day for 12 weeks (Kasper & Dienel); both open-label (no placebo), the latter with a manufacturer employee, Dr. Willmar Schwabe.
  • Depression trials: 340 or 680 mg/day of SHR-5 for 6 weeks (Darbinyan et al.); Drugs.com notes 340–680 mg/day studied up to 12 weeks.
  • Exercise, acute: About 200 mg (about 3% rosavin, 1% salidroside) 60 minutes before exercise (Tinsley et al.); 3 mg/kg one hour before in Noreen et al..
  • Competing dose views: Examine gives 50 mg daily as preventive and 288–680 mg for acute use; ConsumerLab gives 170–680 mg/day in up to two doses; Drugs.com lists 200–600 mg/day.
  • Time of day: Morning to midday; Cropley et al. gave one 200 mg tablet before breakfast and one before lunch; pre-exercise doses precede training by 60 minutes.
  • Half-life and splitting: No human half-life is published; salidroside’s was about 1 hour in rats (Zhang et al.). Trials used twice-daily dosing or one daily tablet.
  • Practitioner use: Layne Norton, speaking with Rhonda Patrick, uses Rhodiola for perceived fatigue and ranks it in his second tier of supplements (FoundMyFitness).
  • Genetics: No genotype-guided dosing exists; the CYP2C9 effect was larger in extensive metabolizers (Thu et al.).
  • Sex: One dose-response trial in resistance-trained adults reported gains regardless of gender (Koozehchian et al.); no sex-specific dosing exists.
  • Age: Studies enrolled mainly adults in their 20s; the EMA limits use to adults over 18 (EMA); no older-adult dosing exists.
  • Baseline biomarkers: No biomarker guides dose; trials selected people by fatigue, burnout or depression scores.
  • Pre-existing conditions: Bipolar disorder and CYP2C9-cleared drug use change the risk balance (see interactions); no condition-specific dosing exists.

Discontinuation & Cycling

  • Duration: Trials lasted from single doses to 12 weeks; no long-term data exist. The EMA advises seeking medical advice beyond two weeks (EMA).
  • Withdrawal effects: No withdrawal syndrome was reported in the trials reviewed here, and searches found no case reports of one.
  • Tapering: No tapering protocol has been published, and none appears needed on current data.
  • Cycling: Four weeks of daily dosing added no endurance benefit beyond acute dosing (De Bock et al.), which fits intermittent use; schedules such as 3–6 weeks on and 1–2 weeks off are practitioner convention, not trial-tested.

Sourcing and Quality

  • Standardization: Most trials used root extract with at least 3% rosavins and 0.8–1% salidroside (Drugs.com); ConsumerLab advises at least 3% rosavins and/or 1% salidrosides as its benchmark.
  • Species authenticity: Rosavins identify Rhodiola rosea; about one fifth of tested products labelled as such lacked them, and Rhodiola crenulata is a suspected substitute (Booker et al.).
  • Contaminants: In a U.S. sample all seven capsule products had trace arsenic, cobalt and lead, two had elevated cobalt and arsenic, and one likely contained added synthetic salidroside (Porwollik & Jafari).
  • Third-party testing: ConsumerLab reports eleven Approved products and two Top Picks from its testing; names are members-only.
  • Clinically studied extracts: SHR-5 (Swedish Herbal Institute, sold as Arctic Root; Thu et al.) and WS 1375 (Dr. Willmar Schwabe, Rosalin; Kasper & Dienel) underlie most trials.
  • Form and sustainability: A tincture (alcohol-based liquid extract) was the strongest CYP inhibitor among six products in vitro (Thu et al.); demand is rising while wild populations decline, so the authors propose cultivated sourcing to ease pressure on wild stands (Brinckmann et al.).

Practical Considerations

  • Time to effect: Single doses were tested about an hour before exercise; life-stress symptoms improved within 3 days and kept improving to week 4 in an open-label study (Edwards et al.).
  • Common pitfalls: Exceeding about 680 mg/day (Examine), buying unverified products (Booker et al.), and expecting daily use to add exercise benefit beyond acute dosing (De Bock et al.).
  • Regulatory status, EU: The EMA treats it as a traditional herbal medicine for temporary relief of stress symptoms in adults over 18, based on long-standing use rather than trial proof (EMA).
  • Regulatory status, U.S.: Sold as a dietary supplement; makers must evaluate safety and labeling before marketing, and the U.S. Food and Drug Administration (FDA) acts against adulterated or misbranded products afterward (FDA).
  • Cost and access: Widely sold over the counter as capsules, tablets and tinctures from many brands; not exceptionally expensive or hard to access.

Interaction with Foundational Habits

  • Sleep: Direction: indirect and uncertain. Drugs.com reports lower doses stimulatory and larger doses sedative, and some trials describing better sleep. Practical consideration: Cropley et al. dosed before breakfast and lunch, not late in the day.
  • Nutrition: Direction: none established in people. In flies, lifespan extension appeared only on diets with protein-to-carbohydrate ratios below 1, and reversed on very high-protein diets (Gospodaryov et al.). Practical consideration: trials set no food rules.
  • Exercise: Direction: potentiating for acute endurance, none for recovery. A single dose an hour before exercise lowered perceived effort (Noreen et al.); 30 days of 600 mg/day left marathon soreness and muscle damage unchanged (Shanely et al.). Practical consideration: timing relative to training matters.
  • Stress management: Direction: direct and modest. Lower self-reported stress than with no treatment (Cropley et al.) and a smaller cortisol response on waking (Olsson et al.), possibly via the HPA axis; no trial compared it with behavioral stress management.

Monitoring Protocol & Defining Success

Baseline testing applies mainly to people using interacting medicines: baseline measures include seated blood pressure, fasting glucose for those on glucose-lowering medicine, INR for those on warfarin, and a fatigue, stress and mood questionnaire score. Healthy users need no routine laboratory panel. Ongoing monitoring follows a cadence of blood pressure rechecks at 1 week and 4 weeks, then every 3 months during continued use; fasting glucose rechecks on the same schedule for users of glucose-lowering medicine; an INR recheck 1–2 weeks after starting for warfarin users; and repeat questionnaires at 4 and 12 weeks. Trials observed symptom changes between 3 days and 12 weeks. Success is a meaningful change from the individual’s own baseline in the targeted symptom, without new side effects.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure (seated, home) No established target; track change from own baseline Safety check: lowering with blood-pressure drugs Average two readings at the same time daily; guideline categories are risk cutoffs, not reference ranges; ConsumerLab notes caution with blood-pressure medicine
Fasting glucose 70–99 mg/dL (standard reference range) Safety check: low blood sugar with glucose-lowering drugs Fast 8–12 hours; only if on glucose-lowering drugs such as insulin or glipizide
INR 0.8–1.2 without anticoagulants (blood thinners; standard reference range); prescriber-set target on warfarin Safety check: CYP2C9 inhibition may raise warfarin effect INR (international normalized ratio, a clotting test); only if on warfarin; effect shown for losartan, not warfarin (Thu et al.)

Qualitative markers include:

  • Fatigue and energy on a validated scale (burnout or vitality questionnaire)
  • Perceived stress and mood, including anxiety
  • Sleep quality and daytime alertness
  • Exercise effort and time to exhaustion, if used for training
  • Side effects: dizziness, dry mouth, restlessness, sleep disruption

Emerging Research

  • Multi-ingredient stress-and-cognition crossover (NCT07319117): Leeds Beckett University, 40 women aged 40–60, formulation containing 100 mg Rhodiola with creatine and others. Registered completion of August 2026 has passed; the record, last updated January 2026, still lists recruiting, with no results. Positive results would not isolate Rhodiola; null results would weaken combination claims.
  • Salidroside and reproductive aging (NCT06990685): Phase 2 (mid-stage efficacy) trial in 370 patients of advanced reproductive age having in vitro fertilization (assisted conception); not yet recruiting, primary completion due January 2027, outcome ongoing pregnancy rate. Positive: a first human aging-related signal; null: the longevity case stays in laboratory work.
  • Adaptogen combination in long COVID (lingering symptoms after infection; NCT04795557): 100 participants took ADAPT-232 (three-herb mix with Rhodiola) or placebo for 14 days; completed December 2021; published, no registry results (Karosanidze et al.): fatigue and pain lasted 1–2 days less in half. Sponsor: extract maker Swedish Herbal Institute. Replication: positive strengthens, null weakens.
  • Coronary microvascular disease (impaired blood flow in the heart’s smallest arteries; NCT04218916): 114 patients planned on 560 mg three times daily versus placebo; status unknown since 2020, registered completion January 2023 has passed, no results posted. A positive result would give a first cardiovascular signal; a null result would leave that case unsupported.
  • Senescent-cell clearance (Furuuchi et al., 2026): For longevity-oriented adults, the mouse study tested only the whole extract in animals; tea-catechin oligomers were implicated in cell-culture work alone. Human tests would strengthen the case, while absent effects would confine it to animals.
  • Independent fatigue replication (Ishaque et al., 2012): A systematic review called for a rigorous trial; the independent placebo-controlled Punja et al. trial was negative, so further independent trials could confirm or overturn the fatigue case.
  • Product-quality surveillance (Porwollik & Jafari, 2026): The U.S. analysis found content far from labels; trials with verified extracts would show whether variable quality explains inconsistent results.

Conclusion

Rhodiola rosea is a root extract used to build resilience to stress, and it is now also discussed as a possible longevity supplement. For health- and longevity-oriented adults, the evidence points to modest, short-lived effects on a limited base. The clearest signal is a small gain in endurance when a dose is taken shortly before exercise, and even that varies between studies. Evidence that it relieves stress-related fatigue is mixed: favorable results come mainly from trials linked to the maker of the leading extract, while the one independent trial with an inactive comparison treatment found the opposite. Evidence for mood is conflicting. Claims about lifespan or aging rest on worms, flies and mice, with no human data on aging outcomes. The main risks are mild side effects, a modest slowing of the liver’s breakdown of some medicines, and uneven product quality, with some products lacking the labeled compounds or carrying trace metals. Overall the evidence consists of small, short trials, many with weak design, and extract makers and supplement sellers have a financial interest in favorable conclusions, whereas the psychiatric societies behind the one guideline cited have no identified revenue from either conclusion. Uncertainty is largest for long-term use, for older adults, and for any effect on how long or how well people live.

Top - Benefits - Risks - Protocol